Skip to main content

Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Citation
Erickson, M. A., and W. A. Banks. “Neuroimmune Axes Of The Blood-Brain Barriers And Blood-Brain Interfaces: Bases For Physiological Regulation, Disease States, And Pharmacological Interventions.”. Pharmacological Reviews, pp. 278-314.
Center University of Washington
Author Michelle A Erickson, William A Banks
Abstract

Central nervous system (CNS) barriers predominantly mediate the immune-privileged status of the brain, and are also important regulators of neuroimmune communication. It is increasingly appreciated that communication between the brain and immune system contributes to physiologic processes, adaptive responses, and disease states. In this review, we discuss the highly specialized features of brain barriers that regulate neuroimmune communication in health and disease. In , we discuss the concept of immune privilege, provide working definitions of brain barriers, and outline the historical work that contributed to the understanding of CNS barrier functions. In , we discuss the unique anatomic, cellular, and molecular characteristics of the vascular blood-brain barrier (BBB), blood-cerebrospinal fluid barrier, and tanycytic barriers that confer their functions as neuroimmune interfaces. In , we consider BBB-mediated neuroimmune functions and interactions categorized as five neuroimmune axes: disruption, responses to immune stimuli, uptake and transport of immunoactive substances, immune cell trafficking, and secretions of immunoactive substances. In , we discuss neuroimmune functions of CNS barriers in physiologic and disease states, as well as pharmacological interventions for CNS diseases. Throughout this review, we highlight many recent advances that have contributed to the modern understanding of CNS barriers and their interface functions.

Year of Publication
2018
Journal
Pharmacological reviews
Volume
70
Issue
2
Number of Pages
278-314
Date Published
12/2018
ISSN Number
1521-0081
DOI
10.1124/pr.117.014647
Alternate Journal
Pharmacol. Rev.
PMID
29496890
PMCID
PMC5833009
Download citation